Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2011-02-10 / Gene Ther. 2011 Jun;18(6):584-93IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells
/in Dendritic Cells, International Publications, Newcastle Disease Virus /von 2011-02-09 / Cancer Res. 2011 Apr;71(7):2497-506Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells
/in Dendritic Cells, Hyperthermia, International Publications /von 2011-02-03 / Clin. Cancer Res. 2011 Apr;17(8):2474-83[Roles of Newcastle disease virus in human acute monocytic leukemia in vitro and in vivo]
/in Acute Leukemia, International Publications, Newcastle Disease Virus /von 2011-02-01 / Zhongguo Dang Dai Er Ke Za Zhi 2011 Feb;13(2):149-52Recent developments in cancer vaccines
/in Dendritic Cells, International Publications /von 2011-02-01 / J. Immunol. 2011 Feb;186(3):1325-31
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution